NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01

NeOnc Technologies (NTHI) announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial’s 25-patient enrollment target. This trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive method designed to bypass the blood-brain barrier through the olfactory and trigeminal nerves. NEO100-01 is the first intranasal therapy of its kind evaluated in malignant gliomas, particularly targeting IDH1 mutant Grade III and IV astrocytomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancer.